Skip to main content

Published locations for SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit

User login

  • Reset your password
  • /content/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or-renal-benefit
  • /hospitalist/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or-renal-benefit
  • /clinicalendocrinologynews/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or
  • /ecardiologynews/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or-renal
  • /cardiology/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or-renal-benefit
  • /endocrinology/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or-renal
  • /type-2-diabetes-icymi/article/221408/diabetes/sglt2-inhibitor-ertugliflozin-shows-no-cv-death-or